A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Summary

The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it.

The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period.

Conditions

• Diabetes Mellitus, Type 1
• Diabetes Mellitus, Type 2

Interventions

DRUG

LY4057996 SC

Administered SC

DRUG

LY4057996 IV

Administered IV

DRUG

Placebo SC

Administered SC

DRUG

Placebo IV

Administered IV

DRUG

Degludec SC

Administered SC

DRUG

Lispro SC

Administered SC

DRUG

Degludec IV

Administered IV

DRUG

Pre-study basal insulin SC

Administered SC

Sponsors & Collaborators

• Eli Lilly and Company

  lead INDUSTRY

Principal Investigators

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-05-16

Primary Completion

2026-12-31

Completion

2026-12-31

Countries

• Germany

Study Locations